MY167596A - Antibiotic formulations - Google Patents
Antibiotic formulationsInfo
- Publication number
- MY167596A MY167596A MYPI2014701634A MYPI2014701634A MY167596A MY 167596 A MY167596 A MY 167596A MY PI2014701634 A MYPI2014701634 A MY PI2014701634A MY PI2014701634 A MYPI2014701634 A MY PI2014701634A MY 167596 A MY167596 A MY 167596A
- Authority
- MY
- Malaysia
- Prior art keywords
- antibiotic formulations
- antibiotic
- suspension formulation
- formulations
- administration
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
- A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0068—Rumen, e.g. rumen bolus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Oncology (AREA)
- Dispersion Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cephalosporin Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
ANTIBIOTIC FORMULATIONS A suspension formulation for administration to an animal, the suspension formulation including: at least one cephalosporin antibiotic or a pharmaceutically similar salt thereof; an oil; and a glycerol acetate solvent.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NZ59738911 | 2011-12-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
MY167596A true MY167596A (en) | 2018-09-20 |
Family
ID=48668892
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MYPI2014701634A MY167596A (en) | 2011-12-23 | 2012-12-21 | Antibiotic formulations |
Country Status (15)
Country | Link |
---|---|
KR (1) | KR20140102319A (en) |
CN (1) | CN104080456A (en) |
AU (1) | AU2012359296B2 (en) |
BR (1) | BR112014014786A2 (en) |
CL (1) | CL2014001602A1 (en) |
CO (1) | CO7101241A2 (en) |
CR (1) | CR20140355A (en) |
DO (1) | DOP2014000146A (en) |
IL (1) | IL233299A0 (en) |
MX (1) | MX2014007735A (en) |
MY (1) | MY167596A (en) |
NI (1) | NI201400064A (en) |
PE (1) | PE20142373A1 (en) |
PH (1) | PH12014501384A1 (en) |
WO (1) | WO2013095166A1 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUE046427T2 (en) | 2012-07-17 | 2020-03-30 | Bayer New Zealand Ltd | Injectable antibiotic formulations and their methods of use |
AU2013290827B2 (en) | 2012-07-17 | 2018-10-18 | Elanco New Zealand | Injectable antibiotic formulations and their methods of use |
KR102671650B1 (en) * | 2019-03-06 | 2024-06-04 | 조에티스 서비시즈 엘엘씨 | Ready-to-use injectable formulation |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU614465B2 (en) * | 1989-04-05 | 1991-08-29 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Medicinal emulsions |
KR20040015622A (en) * | 2002-08-13 | 2004-02-19 | 대한뉴팜(주) | Injectable Composition Comprising Ceftiofur Sodium as Active Ingredient |
CN1517090A (en) * | 2003-01-20 | 2004-08-04 | 王玉万 | Animal use suspensoid injection or emulsion containing antibacterial medicine |
US7767860B2 (en) * | 2007-09-06 | 2010-08-03 | Auspex Pharmaceuticals, Inc | Substituted amino alcohols |
CN101401787B (en) * | 2008-11-19 | 2011-05-18 | 肖希龙 | Ceftiofur long-acting injection and preparation method thereof |
CN101953889B (en) * | 2010-09-07 | 2013-04-10 | 西北农林科技大学 | Compound ceftiofur suspension emulsion injection and preparation method thereof |
-
2012
- 2012-12-21 WO PCT/NZ2012/000245 patent/WO2013095166A1/en active Application Filing
- 2012-12-21 PE PE2014001010A patent/PE20142373A1/en not_active Application Discontinuation
- 2012-12-21 AU AU2012359296A patent/AU2012359296B2/en active Active
- 2012-12-21 CN CN201280063872.1A patent/CN104080456A/en active Pending
- 2012-12-21 KR KR1020147020501A patent/KR20140102319A/en not_active Application Discontinuation
- 2012-12-21 BR BR112014014786A patent/BR112014014786A2/en not_active Application Discontinuation
- 2012-12-21 MX MX2014007735A patent/MX2014007735A/en unknown
- 2012-12-21 MY MYPI2014701634A patent/MY167596A/en unknown
-
2014
- 2014-06-18 PH PH12014501384A patent/PH12014501384A1/en unknown
- 2014-06-18 CL CL2014001602A patent/CL2014001602A1/en unknown
- 2014-06-18 DO DO2014000146A patent/DOP2014000146A/en unknown
- 2014-06-20 NI NI201400064A patent/NI201400064A/en unknown
- 2014-06-22 IL IL233299A patent/IL233299A0/en unknown
- 2014-07-22 CR CR20140355A patent/CR20140355A/en unknown
- 2014-07-22 CO CO14158889A patent/CO7101241A2/en unknown
Also Published As
Publication number | Publication date |
---|---|
KR20140102319A (en) | 2014-08-21 |
CL2014001602A1 (en) | 2014-10-24 |
NI201400064A (en) | 2014-11-28 |
DOP2014000146A (en) | 2014-07-31 |
BR112014014786A2 (en) | 2017-06-13 |
AU2012359296A1 (en) | 2013-08-01 |
CR20140355A (en) | 2014-10-29 |
CN104080456A (en) | 2014-10-01 |
AU2012359296B2 (en) | 2014-12-11 |
MX2014007735A (en) | 2014-08-01 |
WO2013095166A1 (en) | 2013-06-27 |
PH12014501384A1 (en) | 2014-09-22 |
PE20142373A1 (en) | 2015-02-11 |
CO7101241A2 (en) | 2014-10-31 |
IL233299A0 (en) | 2014-08-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3040072A4 (en) | Pharmaceutical composition having pyrimidine compound as active ingredient | |
NZ711982A (en) | Cytotoxic and anti-mitotic compounds, and methods of using the same | |
MX2015008627A (en) | Boronic acid derivatives and therapeutic uses thereof. | |
PH12015501993A1 (en) | Pyrazole-amide compound and medicinal uses therefor | |
EP3082817A4 (en) | Compositions for drug administration | |
IT1404931B1 (en) | OPHTHALMIC COMPOSITIONS FOR THE ADMINISTRATION OF LIPO-SOLUBLE ACTIVE PRINCIPLES. | |
PH12015502178A1 (en) | Pyridinylpyrazoloquinoline compound | |
MX363530B (en) | Tricyclic benzoxaborole compound, preparation method therefor, and use thereof. | |
UA115357C2 (en) | Pyridin-4-yl derivatives | |
EP3024475B8 (en) | Pharmaceutical compositions for intraocular administration comprising an antibacterial agent and an antiinflammatory agent | |
MX2016001422A (en) | Pharmaceutical compositions of fingolimod. | |
WO2014062838A3 (en) | Pkm2 modulators and methods for their use | |
WO2011142731A3 (en) | Formulations comprising a third generation cephalosporin and clavulanic acid | |
PH12014501384A1 (en) | Antibiotic formulations | |
EP2871187A4 (en) | Novel compound or pharmaceutically acceptable salt thereof, and pharmaceutical composition containing same as active ingredient | |
EP2722322B8 (en) | 1,3-di-oxo-indene derivative, pharmaceutically acceptable salt or optical isomer thereof, preparation method thereof, and pharmaceutical composition containing same as an antiviral, active ingredient | |
AU2013338098A8 (en) | Solid salt form of alpha-6-mPEG6-O-hydroxycodone as opioid agonists and uses thereof | |
BR112014022687A2 (en) | USE OF AN EFFECTIVE AMOUNT OF R-P88 OR A PHARMACEUTICALLY ACCEPTABLE SALT OF THE SAME, OR AN ESTER OF THE SAME OR A PHARMACEUTICALLY ACCEPTABLE SALT OF AN ESTER OF THE SAME, PHARMACEUTICAL COMPOSITION, R-P88 OR A PHARMACEUTICALLY ACCEPTABLE SALT, OR A PHARMACEUTICALLY ACCEPTABLE SALT OF THE SAME OR A PHARMACEUTICALLY ACCEPTABLE SALT OF AN ESTER OF THE SAME | |
WO2013095319A3 (en) | Formulations of flurbiprofen and diacerein | |
MX2016000775A (en) | Pharmaceutical preparation comprising aminopyrazole derivative. | |
UY34839A (en) | ANTIBIOTIC FORMULATIONS | |
AR092841A1 (en) | ANTIBIOTIC FORMULATIONS | |
EP3363799A4 (en) | Pharmaceutical composition containing, as active ingredient, 7-azaindolin-2-one derivative or pharmaceutically acceptable salt thereof | |
UA83604U (en) | Pharmaceutical composition | |
TR201106009A2 (en) | Use of the cephalosporin derivative in a pharmaceutical composition. |